Q4 EPS Estimates for Rani Therapeutics Cut by HC Wainwright

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Equities researchers at HC Wainwright cut their Q4 2026 earnings per share (EPS) estimates for shares of Rani Therapeutics in a report released on Friday, August 21st. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.06) per share for the quarter, down from their previous forecast of ($0.05). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Rani Therapeutics’ FY2027 earnings at ($0.20) EPS, FY2028 earnings at ($0.15) EPS and FY2029 earnings at ($0.24) EPS.

Rani Therapeutics (NASDAQ:RANI) last announced its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.93 million.

A number of other research firms have also commented on RANI. Canaccord Genuity Group reiterated a “buy” rating and set a $5.00 price objective on shares of Rani Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Chardan Capital began coverage on shares of Rani Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Rani Therapeutics Stock Down 0.1%

NASDAQ RANI opened at $0.88 on Tuesday. Rani Therapeutics has a fifty-two week low of $0.44 and a fifty-two week high of $3.87. The business has a fifty day moving average of $0.78 and a 200-day moving average of $0.95. The stock has a market cap of $108.89 million, a price-to-earnings ratio of -3.26 and a beta of 0.78.

Insider Activity

In other Rani Therapeutics news, CEO Talat Imran acquired 35,000 shares of the firm’s stock in a transaction dated Friday, July 17th. The shares were acquired at an average price of $0.72 per share, for a total transaction of $25,200.00. Following the completion of the acquisition, the chief executive officer directly owned 469,736 shares of the company’s stock, valued at $338,209.92. This trade represents a 8.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 26.73% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC purchased a new stake in Rani Therapeutics during the second quarter valued at about $2,670,190,000. Almitas Capital LLC acquired a new position in shares of Rani Therapeutics in the 2nd quarter valued at about $7,111,000. Seven Fleet Capital Management LP purchased a new stake in shares of Rani Therapeutics during the 2nd quarter worth about $1,011,299,000. Bank of America Corp DE acquired a new stake in Rani Therapeutics during the 2nd quarter worth approximately $706,000. Finally, AWM Investment Company Inc. purchased a new position in Rani Therapeutics in the second quarter valued at approximately $5,703,000. Institutional investors and hedge funds own 30.19% of the company’s stock.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.